Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Rituxan Prescribers: Rheumatologists(?)

Council Members in this Study Group: 35

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Ara Dikranian, MD
Partner
San Diego Arthritis Medical Clinic

Ara Dikranian, MD, is a Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in Internal Medicine and Rheumatology. He completed his rheumatology training at the University of California San Diego. He has...

Dipti Doshi, MD
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP

Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...

Avram Goldberg, MD,FACR, Assistant Professor , Albert Einstein College of MedicineAvram Goldberg, MD,FACR
Assistant Professor
Albert Einstein College of Medicine

Avram Goldberg, MD, FACR, is an Attending Physician at North Shore University Hospital and an Assistant Professor at the Albert Einstein College of Medicine, New York. He is part of the Division of Rheumatology where he is responsible for treatment of autoimmune and musculoskeletal diseases including...

Kenneth Nies, MD, FACP
Rheumatologist
Arthritis and Osteoporosis Treatment Center

Kenneth Nies, MD, FACP, is a Clinical Professor of Medicine at the University of California Los Angeles and is also in private practice at the Arthritis and Osteoporosis Treatment Center in Torrance, California. In addition to his clinical work, his background includes 10 years of academic medicine...

Daniel Furst, MD
Carl M. Pearson Chair of Rheumatology
UNIVERSITY OF CALIFORNIA LOS ANGELES

Daniel Furst, MD, is the Carl M. Pearson Chair of Rheumatology and Director of Interventional Therapeutics at University of California, Los Angeles Medical Center for Health Sciences. Dr. Furst has expertise in clinical pharmacology of anti-rheumatic drugs, scleroderma, and rheumatoid arthritis.

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
TRU-015 and SBI-087 both trubion's product both strong products with Different MOA , B cell depletion. | 05-01-2008
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...

Phase 2 study showing that a 1mg treatment with Adlea(TM) effective for 12 week persistant pain in OA patients | 07-04-2007
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...

Roche's market share will go up . | 06-18-2007
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Very important new treatment emerging in field of rheumatoid arthritis along with other drugs in pipeline. IL-6 receptor blocker. New Mechanism of action. Has positive priliminary endpoint results at 24 week study for RA compared to DMARD therapy alone.

SRV in non responders | 05-28-2007
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Academic Institution*
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Director
  • Physician - Division Head
  • Professor
  • Medical Director
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-05T01:45:24.617